Jessica A. Sorrentino, Ph.D.
Affiliations: | 2013 | Toxicology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Toxicology, GeneticsGoogle:
"Jessica Sorrentino"Parents
Sign in to add mentor| Norman E. Sharpless | grad student | 2013 | UNC Chapel Hill | |
| (The effects of chronic and acute toxicological exposures on the expression of the tumor suppressor p16INK4a.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lai AY, Sorrentino JA, Dragnev KH, et al. (2020) CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. Journal For Immunotherapy of Cancer. 8 |
| Andreano KJ, Wardell SE, Baker JG, et al. (2020) G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment |
| Bulat I, Maglakelidze M, Murias C, et al. (2020) Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer Cancer Research |
| Weiss JM, Csoszi T, Maglakelidze M, et al. (2019) Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology |
| Liu JY, Souroullas GP, Diekman BO, et al. (2019) Cells exhibiting strong promoter activation in vivo display features of senescence. Proceedings of the National Academy of Sciences of the United States of America |
| O'Shaughnessy J, Wright G, Thummala A, et al. (2019) Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Research. 79 |
| Dai B, Freed DM, Sorrentino JA, et al. (2019) Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens Cancer Research. 79: 4732-4732 |
| Berz D, Spira A, Gadgeel S, et al. (2019) Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results Annals of Oncology. 30: v631 |
| Dees E, Aftimos P, van Oordt H, et al. (2019) Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC) Annals of Oncology. 30: v121-v122 |
| Sorrentino JA, Lai A, Weiss JM, et al. (2018) Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii598 |